Printer Friendly Printed from http://www.researchandmarkets.com/reports/306450 Aurora Kinase inhibitors - The dawn of a new approach to cancer Description: Cell cycle inhibitors represent a key approach to the treatment of cancer. Therapeutic agents have traditionally targeted early stages of the cell cycle (ie the G1/S phase checkpoint or the S phase) or mitotic spindle formation as exemplified by the alkaloids. Recently a new approach to cell cycle regulation has emerged with the identification of the Aurora kinase family. This family plays a role in later stages of the cell cycle from the G2/M check point all the way through to the mitotic checkpoint and late mitosis. Aurora Kinase Inhibitors: The dawn of a new approach to cancer was written as a target evaluation/drug development update report. This analysis was intended to provide a framework for all organizations considering entry into this exciting field or those already in the field but who require competitive intelligence within the area. The report: - Introduces the Aurora kinases - Analyzes the proof of concept supporting the development of aurora kinase inhibitors for the treatment of cancer - Discusses mechanism of action - Evaluates drugs in development - Provides strategic guidance on kinase selectivity - Discusses the promise and risks of kinase inhibitors - Offers competitive intelligence discussing how Aurora kinase inhibitors would fit into the current oncology treatment area. The report compares this class with existing and emerging classes and evaluates the part that Aurora kinase inhibitors could play in the combinatorial approach to cancer Contents: 1. Summary 2. Background 3. The Protein Kinases Tyrosine Kinases - Targets of the First Approved Kinase Inhibitors The Emergence of Serine-Threonine Kinases Genetics & Biochemisty of the Aurora kinases Identification of the Aurora Kinases 4. Physiological Role of the Aurora Kinases 5. Overexpression/Altered Activity of Aurora Kinases in Pathological States 6. Cellular Consequences of Overexpression/Altered Activity of Aurora Kinases 7. In vitro Effect of Aurora Kinase Inhibition 8. Development of Aurora Kinase Inhibitors 9. Strategic & Competitive Analysis Issues surrounding the development of Aurora Kinase inhibitors Can Aurora kinase inhibitors be considered targeted anticancer agents? Interaction with other therapeutics Would inhibitors be expected to be chemopreventative or therapeutic? Is mitotic interruption desirable or should our focus be reinstating the G2/M checkpoint Which Aurora kinases should be targeted? Competitive analysis Antimetabolites Plant alkaloids Integration of Aurora kinase inhibitors into combination therapies including established cytotoxic agents Summary: Our understanding of the Aurora kinase family and its role in cell division has advanced over recent years and the drug discovery community is now in a good position to judge the proof of concept supporting the development of Aurora kinase inhibitors. The body of data reported in Aurora Kinase Inhibitors: The dawn of a new approach to cancer suggests the Aurora kinase family meets many of the criteria that need to be satisfied to put drug discovery efforts into the development of Aurora kinase inhibitors. There is bountiful evidence to support a role for of Aurora kinases in cellular events that become defective in cancer, namely cell cycling; overexpression of the kinases in various cancers is convincing; manipulations that increase Aurora kinase activity have been shown to promote various cellular events consistent with tumorigenesis and; perhaps most convincingly the farthest advanced inhibitor to date has just entered the clinic having demonstrated impressive anticancer efficacy in well designed and pertinent preclinical models. A number of issues are however outstanding that should be addressed in order to optimize the development of the Aurora kinase field. These include an appreciation of how targeted to cancer cells Aurora kinase inhibitors can be; likely interactions (positive or negative) with existing agents; at which stage in tumor progression such inhibitors may be most effective; and an understanding of the benefits and risks of producing catastrophic mitotic damage such is seen with Aurora kinase inhibition. This report offers a strategic analysis of each of these issues, evaluates the first wave of Aurora kinase inhibitors, and makes recommendations on future directions. Ordering: Order Online - visit http://www.researchandmarkets.com/reports/306450 Order by Fax - using the order form below Order By Post - print the order form below and send to Research and Markets, Guinness Centre, Taylors Lane, Dublin 8, Ireland. Page 1 of 2 Printed 30/08/2008 17:03:09 Fax Order Form To place an order via fax simply print this form, fill in the information below and fax the completed form to the number at the bottom of this page. If you have any questions please email help@researchandmarkets.com Order information Please verify that the product information is correct and select the format you require. Product Name: Aurora Kinase inhibitors - The dawn of a new approach to cancer Web Address: http://www.researchandmarkets.com/reports/306450 Office Code: OCHGMLPMNWR Report formats Please enter the quantity of the report format you require. Format Quantity Price Electronic €968.00 Electronic (PDF) - Enterprisewide €1,672.00 Contact information Please enter all the information below in BLOCK CAPITALS. First Name:   Last Name:   Email Address: Job Title: Organisation: Address: City: Postal/Zip Code: Country: Phone Number: Fax Number: Please fax this form to: (646)607-1907 or (646)964-6609 - From USA +353-1-481-1716 or +353-1-653-1571 - From Rest of World Page 2 of 2 Printed 30/08/2008 17:03:09 Payment information Please indicate the payment method you would like to use by selecting the appropriate box.  Pay by Credit Card: American Express Diners Club Master Card Visa Cardholder Name: Expiry Date: / Card Number: CVV Security Code: Issue Date: /   (Diners Club only)  Pay by Check: Please post the check, accompanied by this form, to: Research and Markets, Guinness Centre, Taylors Lane, Dublin 8, Ireland.  Pay by Wire Transfer: Please transfer funds to: Account number: 83313083 Sort code: 98-53-30 Swift code: ULSBIE2D IBAN number: IE78ULSB98533083313083 Bank Address: Ulster Bank, 27-35 Main St, Blackrock, Co. Dublin, Ireland. If you have a Marketing Code please enter it below: Marketing Code: Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp Please fax this form to: (646)607-1907 or (646)964-6609 - From USA +353-1-481-1716 or +353-1-653-1571 - From Rest of World